lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

Functional Genomics Identifies Multiple Clinically Actionable Resistance Mechanisms to CDK4/6 Inhibition in Bladder Cancer

33 Pages Posted: 23 Apr 2019

See all articles by Zhichao Tong

Zhichao Tong

Technische Universität München (TUM) - Department of Urology

Anuja Sathe

Technische Universität München (TUM) - Department of Urology

Benedikt Ebner

Technische Universität München (TUM) - Department of Urology

Pan Qi

Technische Universität München (TUM) - Department of Urology

Christian Veltkamp

Technische Universität München (TUM)

Juergen E. Gschwend

Technische Universität München (TUM) - Department of Urology

Per Sonne Holm

Technische Universität München (TUM) - Department of Urology

Roman Nawroth

Technische Universität München (TUM) - Department of Urology

More...

Abstract

Background: CDK4/6 inhibitors are in combination with chemotherapy or small molecules effective compounds in tumor therapy. This study was performed to reveal predictive markers, mechanisms of resistance and to develop rational combination therapies for a personalized therapy approach in bladder cancer.

Methods: A genome-scale CRISPR-dCas9 activation screen for resistance to the CDK4/6 inhibitor Palbociclib was performed in the bladder cancer derived cell line T24. sgRNA counts were analyzed using next generation sequencing and MAGeCK-VISPR. Significantly enriched sgRNAs were cloned and validated on a molecular and functional level for mediating resistance to Palbociclib treatment. Analysis was done in vitro and in vivo in the chorioallantois mebrane model of the chicken embryo. Comparison of screen hits to signaling pathways and clinically relevant molecular alterations was performed using DAVID, Reactome, DGIdb and cBioPortal.

Findings: In the screen, 1024 sgRNAs encoding for 995 genes were significantly enriched and 8 random sgRNAs were validated, revealing partial rescue to Palbociclib treatment. Within this gene panel, members of Receptor-Tyrosine Kinases, PI3K-Akt, Ras/MAPK, JAK/STAT or Wnt signaling pathways were identified. Combination of Palbociclib with inhibitors against these signaling pathways revealed beneficial effects in vitro and in vivo xenografts

Interpretation: Identification of potential predictive markers, resistance mechanisms and rational combination therapies could be achieved by applying a CRISPR-dCas9 approach in bladder cancer.

Funding: This work has been supported by the China Scholarship Council (ZT, QP) and the Fritz-Thyssen foundation (AS). This work was also supported by Pfizer pharma inc. grant IIR WI207703.

Declaration of Interest: The authors declare no potential conflicts of interest.

Ethical Approval: In accordance with the law of Germany and the District Government of upper Bavaria, the chicken embryos involved in this manuscript were sacrificed at Embryo Day 15, thus no need for additional ethics approval.

Keywords: Bladder cancer; CDK4/6 inhibition; CRISPR; Resistance; Combination therapies

Suggested Citation

Tong, Zhichao and Sathe, Anuja and Ebner, Benedikt and Qi, Pan and Veltkamp, Christian and Gschwend, Juergen E. and Holm, Per Sonne and Nawroth, Roman, Functional Genomics Identifies Multiple Clinically Actionable Resistance Mechanisms to CDK4/6 Inhibition in Bladder Cancer (04/15/2019 14:57:42). Available at SSRN: https://ssrn.com/abstract=3373842 or http://dx.doi.org/10.2139/ssrn.3373842

Zhichao Tong

Technische Universität München (TUM) - Department of Urology

Germany

Anuja Sathe

Technische Universität München (TUM) - Department of Urology

Germany

Benedikt Ebner

Technische Universität München (TUM) - Department of Urology

Germany

Pan Qi

Technische Universität München (TUM) - Department of Urology

Germany

Christian Veltkamp

Technische Universität München (TUM)

Arcisstrasse 21
Munich, DE 80333
Germany

Juergen E. Gschwend

Technische Universität München (TUM) - Department of Urology

Germany

Per Sonne Holm

Technische Universität München (TUM) - Department of Urology

Germany

Roman Nawroth (Contact Author)

Technische Universität München (TUM) - Department of Urology ( email )

Germany

Click here to go to TheLancet.com

Paper statistics

Abstract Views
419
Downloads
24